Last10K.com

Alexion Pharmaceuticals, Inc. (ALXN) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2019

SEC Filings

Alexion Pharmaceuticals, Inc.

CIK: 899866 Ticker: ALXN




a2016earningsreleaseimagea27.jpg
Alexion Reports Third Quarter 2019 Results

3Q19 total revenues of $1,263.1 million, a 23 percent increase over 3Q18 and a 23 percent volume increase

3Q19 GAAP diluted EPS of $2.08; non-GAAP diluted EPS of $2.79

Received 2 recent regulatory approvals - ULTOMIRIS® (ravulizumab-cwvz) for atypical hemolytic uremic syndrome (aHUS) in the U.S. and SOLIRIS® (eculizumab) for adults with neuromyelitis optica spectrum disorder (NMOSD) in the EU

Announced agreement to acquire Achillion Pharmaceuticals

Continued disciplined business development execution with Eidos and Stealth BioTherapeutics collaborations

Increased revenues and EPS guidance to reflect strong business and continued growth

BOSTON, October 23, 2019 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2019. Total revenues in the third quarter were $1,263.1 million, a 23 percent increase compared to the same period in 2018. The negative impact of foreign currency on total revenues year-over-year was less than 1 percent, or $2.5 million, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $2.08, a 41 percent increase versus the prior year. Non-GAAP diluted EPS for the third quarter of 2019 was $2.79, a 38 percent increase versus the third quarter of 2018.

"With consistent and strong execution, we have delivered another record performance in the third quarter, building on our momentum from the first half of 2019. Our teams continued to demonstrate launch excellence across the globe, with very rapid starts to the German and Japanese ULTOMIRIS PNH launches, where conversion is progressing ahead of the best-in-class U.S. launch at the same time points, as well as a strong start to the SOLIRIS NMOSD launch in the U.S.," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "We also continued to expand our portfolio with two additional approvals - ULTOMIRIS for atypical HUS in the U.S. and SOLIRIS for NMOSD in the EU - and three new business development transactions that further diversify our pipeline, including an agreement to acquire Achillion. By continuing to deliver on the ambitious transformation plan we laid out two-and-a-half years ago, we have successfully established a strong foundation for the future and look forward to building on this progress as we advance our mission of delivering life-changing therapies to people with rare diseases."
 
Third Quarter 2019 Financial Highlights

Total net product sales were $1,263.1 million in the third quarter of 2019, compared to $1,026.5 million in the third quarter of 2018.


1

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Wednesday, October 23, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexion Pharmaceuticals, Inc..

Continue

Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Cash Flow
Income
Shares
Geography
Product
Earnings
Other
Inside Alexion Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information Document
Restructuring And Related Expenses (Schedule Of Restructuring And Related Costs) (Details)
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Changes In Stockholder's Equity Statement
Condensed Consolidated Statements Of Comprehensive Income (Parenthetical)
Condensed Consolidated Statements Of Comprehensive Income Statement
Condensed Consolidated Statements Of Operations
(Restructuring Reserve Roll Forward) (Details)
Acquisitions
Acquisitions (Narrative) (Details)
Acquisitions (Summary Of Total Consideration) (Details)
Acquisitions (Tables)
Basis Of Presentation And Principles Of Consolidation
Basis Of Presentation And Principles Of Consolidation Basis Of Presentation And Principles Of Consolidation (Details)
Business
Commitments And Contingencies
Commitments And Contingencies (Narrative) (Details)
Debt
Debt (Details)
Defined Benefit Plans
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Narrative) (Details)
Derivative Instruments And Hedging Activities (Offsetting Assets And Liabilities) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Interest Rate Contracts) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)
Derivative Instruments And Hedging Activities (Tables)
Earnings Per Common Share
Earnings Per Common Share (Narrative) (Details)
Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details)
Earnings Per Common Share (Tables)
Fair Value Measurement
Fair Value Measurement (Narrative) (Details)
Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)
Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)
Fair Value Measurement (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Schedule Of Income Tax Provision And Effective Tax Rate) (Details)
Income Taxes (Tables)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Narrative) (Details)
Intangible Assets And Goodwill (Schedule Of Intangible Assets And Goodwill) (Details)
Intangible Assets And Goodwill (Tables)
Inventories
Inventories (Details)
Inventories (Tables)
Leases
Leases (Tables)
Leases - Finance And Operating Lease Liability Maturity (Details)
Leases - Lease Additional Information (Details)
Leases - Lease Assets And Liabilities (Details)
Leases - Lease Cash Flow Information (Details)
Leases - Lease Related Costs (Details)
Leases - Narrative (Details)
Marketable Securities
Marketable Securities (Available-For-Sale Debt Securities By Contractual Maturity) (Details)
Marketable Securities (Available-For-Sale Investments By Classification In Balance Sheet) (Details)
Marketable Securities (Narrative) (Details)
Marketable Securities (Summary Of Securities Held) (Details)
Marketable Securities (Tables)
Other Comprehensive Income And Accumulated Other Comprehensive Income
Other Comprehensive Income And Accumulated Other Comprehensive Income (Changes In Aoci) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Significant Reclassifications From Aoci) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Tables)
Other Investments
Other Investments (Details)
Restructuring And Related Expenses
Restructuring And Related Expenses (Narrative) (Details)
Restructuring And Related Expenses (Tables)
Revenue Recognition
Revenue Recognition (Disaggregation Of Revenue By Product And Geographical Region) (Details)
Revenue Recognition (Summary Of Receivables And Contract Liabilities From Contracts) (Details)
Revenue Recognition (Tables)
Stockholders' Equity
Stockholders' Equity (Details)
Subsequent Events
Subsequent Events (Details)
Ticker: ALXN
CIK: 899866
Form Type: 10-Q Quarterly Report
Accession Number: 0000899866-19-000099
Submitted to the SEC: Wed Oct 23 2019 3:56:30 AM EST
Accepted by the SEC: Wed Oct 23 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alxn/0000899866-19-000099.htm